baclofen has been researched along with Alcohol Abuse in 217 studies
Excerpt | Relevance | Reference |
---|---|---|
"Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 9.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
" A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0." | 9.19 | Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014) |
"Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis." | 9.12 | Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007) |
"90 patients with alcoholism stage II suffering from secondary affective disorders (anxiety, depression) were divided into 4 groups: treated with GABA-B-receptor ligand baclofen (group 1), with sibazon (group 2), amitriptylin (group 3), placebo (group 4)." | 9.07 | [The use of baclofen for treating affective disorders in alcoholism]. ( Borodkin, IuS; Burakov, AM; Grinenko, AIa; Ivanov, VB; Karandashova, GF; Krupitskiĭ, EM; Lapin, IP, 1994) |
"Baclofen, a very potent agonist of the GABA system, has anti-craving properties that can provide to this old drug, usually prescribed against spasticity, a new interest in the treatment of alcoholism." | 8.87 | [Baclofen: the new miracle cure for alcoholism?]. ( Gache, P, 2011) |
"Baclofen self-poisoning by alcohol-dependent patients is a serious concern for the French health authorities." | 7.85 | Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. ( Cardona, F; de Haro, L; Franchitto, N; Pelissier, F; Picot, C; Puskarczyk, E; Sapori, JM; Tournoud, C, 2017) |
"The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment." | 7.80 | Severe tinnitus induced by off-label baclofen. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Gautier, S; Hennaux, C; Loche, V; Rolland, B, 2014) |
"Baclofen safety was evaluated by adverse reaction occurrence during treatment." | 7.01 | Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023) |
"Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual-guided counseling." | 6.84 | The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. ( Dieperink, E; Fuller, B; Hauser, P; Ho, SB; Kern, S; Thuras, P, 2017) |
"A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 5.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
" HDB induces frequent neuropsychiatric adverse events (AEs)." | 5.42 | Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015) |
"Data from a randomised controlled trial (RCT) (N = 104), in which AUD patients received placebo or baclofen (30 mg/day or 75 mg/day) for 12 weeks, were analysed to determine predictive effects of the following four clinical characteristics: alcoholic liver disease (ALD), baseline alcohol consumption, craving and anxiety." | 5.30 | Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. ( Baillie, A; Haber, PS; Morley, KC; Rombouts, SA, 2019) |
"Baclofen did not lead to a differential change in cognitive biases compared with placebo, and trait anxiety levels did not moderate this." | 5.27 | Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein? ( Beraha, EM; Krediet, E; Salemink, E; Wiers, RW, 2018) |
" Baclofen has been shown to promote abstinence, to reduce craving, and to reduce anxiety in alcohol-dependent individuals, and it promises to be a useful agent, although clinical data are limited at present." | 5.24 | Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. ( Arora, S; Elwadhi, D; Gupta, M; Rastogi, R; Verma, P, 2017) |
" A post hoc analysis stratifying according to whether there had been a comorbid anxiety disorder, revealed a beneficial effect of baclofen 30 mg/day versus placebo on time to lapse and relapse (P < 0." | 5.19 | Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety. ( Addolorato, G; Baillie, A; Haber, PS; Leggio, L; Leung, S; Morley, KC, 2014) |
"Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis." | 5.12 | Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007) |
"90 patients with alcoholism stage II suffering from secondary affective disorders (anxiety, depression) were divided into 4 groups: treated with GABA-B-receptor ligand baclofen (group 1), with sibazon (group 2), amitriptylin (group 3), placebo (group 4)." | 5.07 | [The use of baclofen for treating affective disorders in alcoholism]. ( Borodkin, IuS; Burakov, AM; Grinenko, AIa; Ivanov, VB; Karandashova, GF; Krupitskiĭ, EM; Lapin, IP, 1994) |
" Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism." | 5.01 | Baclofen for alcohol withdrawal. ( Liu, J; Wang, LN, 2019) |
"Baclofen, a very potent agonist of the GABA system, has anti-craving properties that can provide to this old drug, usually prescribed against spasticity, a new interest in the treatment of alcoholism." | 4.87 | [Baclofen: the new miracle cure for alcoholism?]. ( Gache, P, 2011) |
" Different lines of evidence indicate that direct agonists, including baclofen, effectively suppress acquisition and maintenance of alcohol drinking behavior, relapse-like drinking, and alcohol's reinforcing, rewarding, stimulating, and motivational properties in rats and mice." | 4.85 | Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. ( Colombo, G; Maccioni, P, 2009) |
"Baclofen self-poisoning by alcohol-dependent patients is a serious concern for the French health authorities." | 3.85 | Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013. ( Cardona, F; de Haro, L; Franchitto, N; Pelissier, F; Picot, C; Puskarczyk, E; Sapori, JM; Tournoud, C, 2017) |
"The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment." | 3.80 | Severe tinnitus induced by off-label baclofen. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Gautier, S; Hennaux, C; Loche, V; Rolland, B, 2014) |
" As baclofen suppressed ethanol self-administration and showed evidence of increased potency in dependent animals, the present experiment suggests that the GABA(B) receptor could be a potential pharmacotherapeutic target for the treatment of chronic alcoholism." | 3.74 | The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. ( Koob, GF; Walker, BM, 2007) |
"These results are in close agreement with those of a preliminary clinical study and suggest that baclofen may constitute a novel therapeutic agent for alcoholism." | 3.70 | Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Lobina, C; Pani, M; Reali, R, 2000) |
"Baclofen has been shown to reduce alcohol consumption in some individuals with alcohol use disorder." | 3.30 | Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results. ( Arunogiri, S; Baillie, A; Haber, PS; Hurzeler, T; Logge, W; Morley, K; Towers, E, 2023) |
"Baclofen was well tolerated and may be considered for the management of alcohol withdrawal syndrome, especially useful in situations where benzodiazepines should be withheld, such as patients with liver impairment." | 3.30 | Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial. ( Crunelle, CL; Jegham, S; Matthys, F; Vanderbruggen, N, 2023) |
"Twenty-eight recently detoxified patients (13 receiving baclofen (BAC), 15 receiving placebo (PLA)) were investigated within a longitudinal, double-blind, and randomized pharmaco-fMRI design with an individually adjusted daily dosage of 30-270 mg." | 3.30 | Effects of baclofen on insular gain anticipation in alcohol-dependent patients - a randomized, placebo-controlled, pharmaco-fMRI pilot trial. ( Beck, A; Charlet, K; Geisel, O; Genauck, A; Gleich, T; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wackerhagen, C; Wüstenberg, T, 2023) |
"Baclofen safety was evaluated by adverse reaction occurrence during treatment." | 3.01 | Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases. ( Chang, C; Cheng, J; Duan, F; Li, J; Liu, C; Song, S; Yang, S; Zhai, H, 2023) |
"Baclofen daily dose was 30 mg to 300 mg: 10 RCTs used low doses (30 mg or less); eight RCTs medium doses (above 30 and 100 mg or less) and four RCTs high doses (above 100 mg)." | 3.01 | Baclofen for alcohol use disorder. ( Agabio, R; Minozzi, S; Rösner, S; Saulle, R, 2023) |
"Both baclofen-treated groups reported fewer post-scan % HDD when compared to the placebo-treated group, but no subjective craving group differences were found." | 3.01 | Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. ( Baillie, AJ; Haber, PS; Logge, WB; Morley, KC; Morris, RW, 2021) |
"Baclofen is a selective GABA-B receptor agonist which has been investigated as a potential treatment for alcohol use disorder." | 3.01 | A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. ( Akhlaghi, F; Deschaine, SL; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Sadighi, A, 2021) |
"Treatment with baclofen further led to a decrease in alcohol cue-modulated functional connectivity between left VTA and left anterior cingulate cortex (ACC) as well as left medial prefrontal cortex (MPFC)." | 2.87 | Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study. ( Beck, A; Charlet, K; Geisel, O; Heinz, A; Lorenz, RC; Müller, CA; Pelz, P; Wüstenberg, T, 2018) |
"Oral baclofen was given at dosages of 0 (placebo) or 30 mg/day over 12 weeks with concomitant manual-guided counseling." | 2.84 | The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. ( Dieperink, E; Fuller, B; Hauser, P; Ho, SB; Kern, S; Thuras, P, 2017) |
"Baclofen was assessed versus placebo for maintenance of abstinence and reduction in alcohol consumption in alcohol-dependent patients." | 2.84 | A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study. ( Aubin, HJ; Dano, C; Dematteis, M; Detilleux, M; Paille, F; Reynaud, M; Trinquet, F; Trojak, B; Zakine, B, 2017) |
"Baclofen has been suggested as a potential pharmacotherapy for alcohol use disorder, but the clinical data are conflicting." | 2.84 | Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. ( Amodio, JP; Bollinger, JW; Farinelli, LA; Farokhnia, M; Lee, MR; Leggio, L; Lionetti, TA; Schwandt, ML; Sewell, L; Spero, DE, 2017) |
"The National institute on Alcohol Abuse and Alcoholism (NIAAA) considers alcohol abuse to be more than 14 units of alcohol a week for men and 7 units for women." | 2.82 | Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial. ( Asehnoune, K; Feuillet, F; Mahe, PJ; Sebille, V; Vourc'h, M, 2016) |
"Previous randomised placebo-controlled trials with low-to-medium doses of baclofen (30-60mg) showed inconsistent results, but case studies suggested a dose-response effect and positive outcomes in patients on high doses of baclofen (up to 270mg)." | 2.82 | Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. ( Bakker, A; Beraha, EM; Bodewits, P; de Jong, D; Defourny, H; Geest, DV; Goudriaan, AE; Salemink, E; Schiphof, T; Smits, N; van den Brink, W; van Tricht, M; Wiers, RW; Zwart, JW, 2016) |
"Harmful alcohol use and alcohol use disorders (AUD) result in major health and community burden worldwide, yet treatment options are limited." | 2.82 | GABA ( Haber, PS; Logge, WB; Morley, KC, 2022) |
"Depression was assessed with Montgomery-Ashberg scale." | 2.80 | [Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence]. ( Alexeeva, YV; Berntsev, VA; Chekhlaty, EI; Kiselev, AS; Krupitsky, EM; Neznanov, NG; Popov, YV; Rybakova, KV; Zubova, EY, 2015) |
"Effective treatments for alcohol use disorders in those with significant liver disease are critically lacking." | 2.78 | The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. ( Baillie, A; Haber, PS; Leung, S; Morley, KC, 2013) |
"Baclofen was associated with a significant reduction in state anxiety (F(1,73)= 5." | 2.75 | Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. ( Flannery, BA; Gallop, R; Garbutt, JC; Kalka-Juhl, L; Kampov-Polevoy, AB, 2010) |
"Baclofen was reasonably tolerated." | 2.71 | Baclofen for alcohol dependence: a preliminary open-label study. ( Cody, MW; Crosby, K; Flannery, BA; Garbutt, JC; Grace, K; Morreale, M; Osborne, M; Renn, W; Trivette, A, 2004) |
" With the background that individualized, rather than fixed, high dosing with baclofen could be critical for success, a large (n = 320), industry-independent, 62-center French RCT (the Bacloville trial) examined whether individually uptitrated, high-dose baclofen could reduce alcohol consumption in heavy drinkers across a year of treatment." | 2.66 | Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption. ( Andrade, C, 2020) |
"Baclofen was superior to placebo with significant increases in TTL (8 RCTs, 852 patients; SMD=0." | 2.58 | Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. ( Beraha, EM; Morley, K; Pierce, M; Sutterland, A; van den Brink, W, 2018) |
"Participants had a diagnosis of alcohol dependence according the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV or the International Classification of Diseases (ICD)-10 criteria who were currently drinking." | 2.58 | Baclofen for alcohol use disorder. ( Minozzi, S; Rösner, S; Saulle, R, 2018) |
" For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function." | 2.58 | Alcohol addiction - the safety of available approved treatment options. ( Addolorato, G; Antonelli, M; Ferrulli, A; Gasbarrini, A; Mirijello, A; Mosoni, C; Rando, MM; Sestito, L; Tarli, C; Vassallo, GA, 2018) |
"Baclofen is a γ-aminobutyric acid B (GABA-B) agonist which is used increasingly as an off-label treatment." | 2.58 | Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. ( Jones, A; Rose, AK, 2018) |
"Baclofen is a promising therapeutic in this area." | 2.55 | Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies. ( Owens, L; Pirmohamed, M; Richardson, P; Thompson, A, 2017) |
"The development of alcohol dependence is associated with significant morbidity and mortality." | 2.55 | Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. ( Goh, ET; Morgan, MY, 2017) |
" However, HDB has been associated with numerous reports of adverse events (AEs)." | 2.53 | Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. ( Auffret, M; Franchitto, N; Rolland, B, 2016) |
"Alcohol use disorders are common, but only a small minority of patients receive adequate treatment." | 2.52 | Recent Developments in Pharmacotherapy of Alcoholism. ( Lieb, M; Soyka, M, 2015) |
"Baclofen has been tested for its capacity to reduce craving for alcohol." | 2.49 | Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013. ( , 2013) |
" Questions still remain about optimal dosing and duration." | 2.48 | Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. ( Gagliardi, JP; Muzyk, AJ; Rivelli, SK, 2012) |
" Thus, baclofen should benefit from further studies of its biobehavioral mechanisms, dose-response effect, and indications in various alcoholic patient profiles." | 2.48 | Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. ( Aubin, HJ; Benyamina, A; Blecha, L; Gorsane, MA; Hache, G; Kebir, O; Reynaud, M, 2012) |
" The outcomes considered were alcohol withdrawal seizures, adverse events and dropouts." | 2.47 | Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. ( Amato, L; Davoli, M; Minozzi, S, 2011) |
" Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis." | 2.46 | Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. ( Addolorato, G; Leggio, L, 2010) |
"Acamprosate has demonstrated efficacy for treating alcohol dependence in European trials, but with a small effect size." | 2.44 | Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. ( Johnson, BA, 2008) |
"Treatment with baclofen also suppressed the number of daily drinks and decreased the obsessive and compulsive components of alcohol craving." | 2.42 | Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. ( Addolorato, G; Agabio, R; Carai, MA; Colombo, G; Gessa, GL; Pibiri, F; Serra, S; Vacca, G, 2004) |
" The usual side effects such as drowsiness were frequent (22%) but no serious adverse events (AEs) or overt encephalopathy related to baclofen was reported." | 1.91 | Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study. ( Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023) |
"Baclofen has been trialled for AUD in cirrhosis and appears to be effective." | 1.72 | Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. ( Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022) |
"R(+)-Baclofen was more effective than RS(±)-Baclofen in reducing ethanol intake and seeking during acute withdrawal and during relapse after abstinence." | 1.62 | Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side. ( Bloch, V; Echeverry-Alzate, V; Jeanblanc, J; Labat, L; Naassila, M; Sauton, P; Soichot, M; Vorspan, F, 2021) |
"Medical management of alcohol use disorders." | 1.51 | [Medical management of alcohol use disorders]. ( Paille, F, 2019) |
"Baclofen exposure was significantly associated with hospitalisation (hazard ratio [HR] = 1." | 1.48 | Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. ( Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M, 2018) |
"Diazepam 20 mg was used up to three times per day, but didn't seem to improve or reduce the anxiety, agitation, visual or auditory hallucinations." | 1.48 | Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence. ( Calvo, ME; Gunnarsson, T; Hao, M; Smith, L, 2018) |
"Baclofen has been shown to reduce alcohol consumption in alcohol-dependent individuals, but there is marked heterogeneity in response." | 1.48 | Moderation of baclofen response by a GABA ( Baillie, A; Dore, G; Fraser, I; Haber, PS; Luquin, N; Morley, KC; Phung, N; Trent, RJ, 2018) |
"Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed." | 1.46 | Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. ( Auffret, M; Baguet, A; Bordet, R; Cabe, N; Carton, L; Cottencin, O; Deheul, S; Dervaux, A; Dib, M; Drelon, M; Duhamel, A; Gautier, S; Grit, I; Guillin, O; Jardri, R; Kemkem, A; Labreuche, J; Lapeyre-Mestre, M; Masquelier, C; Rolland, B; Vabret, F, 2017) |
"Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner." | 1.46 | Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Rolland, B, 2017) |
"Non-baclofen cases had lower rate of endotracheal intubation (n = 1833, 6%, P < 0." | 1.46 | Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre. ( Boels, D; Brunet, M; Le Roux, G; Léger, M; Lerolle, N, 2017) |
" Further randomized studies alongside investigation of dosing strategies are required." | 1.46 | A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. ( Gilmore, I; Owens, L; Pirmohamed, M; Richardson, P; Rose, A; Thompson, A, 2017) |
" At a mean dosage of 40 mg/day (extremes: 30-210), the median daily alcohol consumption reduced from 80 to 0 g/day (P<0." | 1.46 | One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience. ( Barrault, C; Béhar, V; Cadranel, JF; Costentin, C; Garioud, A; Hagège, H; Lison, H; Medmoun, M; Pulwermacher, G; Roudot-Thoraval, F, 2017) |
"Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year." | 1.46 | The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Deheul, S; Duhamel, A; Gautier, S; Labreuche, J; Pignon, B; Rolland, B; Simioni, N, 2017) |
"Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD)." | 1.46 | Speaking fluently with baclofen? ( Beraha, E; Bodewits, P; van den Brink, W; Wiers, R, 2017) |
"A 23-year-old man with a history of alcohol dependence was admitted to our hospital after self-intoxication with 2700 mg baclofen and 330 mg mirtazapine." | 1.43 | [Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms]. ( de Witte, LD; Dekker, D; Kaasjager, K; Kromkamp, M; Veraart, J; Vinkers, CH, 2016) |
"We describe severe central sleep apnea (CSA) in four patients with none of the conditions commonly associated with CSA who were receiving chronic baclofen therapy for alcohol withdrawal." | 1.43 | Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series. ( d'Ortho, MP; Gagnadoux, F; Gentina, T; Joyeux-Faure, M; Launois, SH; Olivier, PY; Pépin, JL, 2016) |
"The treatment of alcohol dependence (AD) is a complex activity as the variables are numerous; however, those which must necessarily be taken into account are the type of AD, the internal comorbidities and the presence of any psychiatric comorbidity." | 1.43 | Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy. ( Borro, P; Leone, S; Testino, G, 2016) |
"Baclofen seekers were more likely to be retained in treatment at 6 months (OR = 3." | 1.43 | Characteristics of Patients with Alcohol Dependence Seeking Baclofen Treatment in France: A Two-Centre Comparative Cohort Study. ( Bence, C; Cottencin, O; Deken, V; Preda, C; Rolland, B; Simioni, N, 2016) |
"Baclofen has been shown to produce enantioselective effects in behavioral assays, including those modeling reflexive and sexual behavior." | 1.42 | Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption. ( Blasingame, SN; Boehm, SL; Kasten, CR, 2015) |
" The mean dosage of baclofen at the onset of the first adverse effect was 83 ± 57 mg/day." | 1.42 | Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study. ( Alexandre-Dubroeucq, C; Jaury, P; Le Jeunne, C; Legay Hoang, L; Pinot, J; Rigal, L, 2015) |
"Baclofen treatment decreased craving in all patients." | 1.42 | Anticraving Effect of Baclofen in Alcohol-Dependent Patients. ( Alvarez, JC; Imbert, B; Simon, N, 2015) |
" The lack of proper recommendations regarding the dosage has important implications for safety in clinical management." | 1.42 | High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern. ( Baby, S; Chand, P; Gowda, GS; Holla, B; Murthy, P; Prabhu, L; Viswanath, B, 2015) |
" HDB induces frequent neuropsychiatric adverse events (AEs)." | 1.42 | Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. ( Auffret, M; Bordet, R; Cottencin, O; Danel, T; Deheul, S; Gautier, S; Langlois, C; Rolland, B; Valin, T, 2015) |
"Baclofen was suggested as a possible cause of the CSAS, and after its withdrawal, a second polysomnography was done, showing the disappearance of the central apneas and a shift to severe obstructive SAS (AHI 43." | 1.42 | Baclofen-Associated Onset of Central Sleep Apnea in Alcohol Use Disorder: A Case Report. ( Besson, M; Cervena, K; Claudel, E; Espa, F; Janssens, JP; Lador, F; Mégevand, P; Pépin, JL; Perogamvros, L; Thorens, G, 2015) |
"We report the case of a woman with both alcohol use disorder and bulimia nervosa." | 1.42 | Efficacy of High-Dose Baclofen for Alcohol Use Disorder and Comorbid Bulimia: A Case Report. ( Bertschy, G; Lalanne, L; Riegert, M; Weibel, S, 2015) |
"Baclofen has been increasingly used in the treatment of alcohol withdrawal syndrome (AWS)." | 1.40 | Increase of baclofen intoxications: risks involved and management. ( Arbouw, ME; Hoge, HL; Jansman, FG; Meulenbelt, J, 2014) |
"In the alcohol dependence group, median duration of baclofen treatment was 143." | 1.40 | Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study. ( Dupouy, J; Fournier, JP; Jouanjus, É; Lapeyre-Mestre, M; Oustric, S; Palmaro, A; Poutrain, JC, 2014) |
"Baclofen is a γ-aminobutyric acid B (GABA-B) receptor agonist that is approved for spasticity." | 1.40 | Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. ( Bence, C; Bordet, R; Carton, L; Cottencin, O; Deheul, S; Jaillette, E; Rolland, B; Saulnier, F, 2014) |
"Baclofen is a GABA-B receptor agonist used in the treatment of spasticity." | 1.40 | High variability in the exposure of baclofen in alcohol-dependent patients. ( Alvarez, JC; Grassin-Delyle, S; Imbert, B; Jaquet, I; Lançon, C; Marsot, A; Simon, N, 2014) |
"Starting from 2002, an Alcohol Addiction Unit (AAU) was formed within the liver transplant center for the management of alcoholic patients affected by end-stage liver disease and included in the waiting list for transplantation." | 1.39 | Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. ( Addolorato, G; Agnes, S; Cossari, A; D'Angelo, C; Ferrulli, A; Gasbarrini, A; Gasbarrini, G; Landolfi, R; Leggio, L; Mirijello, A; Vassallo, G, 2013) |
"Alcohol dependence is associated with a wide array of physical and psychiatric complications and is a major cause of morbidity and mortality worldwide." | 1.38 | High-dose baclofen for treatment-resistant alcohol dependence. ( Currie, J; Jones, DM; Pastor, A, 2012) |
"Baclofen is a safe and well-tolerated novel drug treatment for alcohol dependence." | 1.38 | Baclofen for the treatment of alcohol dependence. ( Howland, RH, 2012) |
"Baclofen is a gamma amino butyric acid (GABA) derivative that is a specific agonist at GABA-B receptors." | 1.37 | Baclofen-induced morbiliform rashes: a case series. ( Benegal, V; Jayaram, N; Manjunatha, N; Saddichha, S, 2011) |
"Baclofen has been studied for the treatment of alcohol withdrawal, but current research is limited." | 1.34 | Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. ( Schrader, S; Stallings, W, 2007) |
"Current pharmacotherapies for alcohol dependence in humans (e." | 1.32 | Rats on the grog: novel pharmacotherapies for alcohol craving. ( Gallate, JE; McGregor, IS, 2004) |
"Baclofen was orally administered for 4 weeks, at a dose of 15 mg/day refracted in three times per day for the first 3 days, with the dose increased to 30 mg/day for the remaining 27 days." | 1.31 | Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. ( Addolorato, G; Capristo, E; Caputo, F; Colombo, G; Gasbarrini, G; Gessa, GL, 2000) |
"Baclofen was largely ineffective in reducing withdrawal-induced tremors, although it was capable of producing sedation of a different type than that produced by phenobarbitol and ethanol." | 1.26 | The effects of ethanol, phenobarbital, and baclofen on ethanol withdrawal in the rhesus monkey. ( Tarika, JS; Winger, G, 1980) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.46) | 18.7374 |
1990's | 4 (1.84) | 18.2507 |
2000's | 33 (15.21) | 29.6817 |
2010's | 141 (64.98) | 24.3611 |
2020's | 38 (17.51) | 2.80 |
Authors | Studies |
---|---|
Burnette, EM | 1 |
Nieto, SJ | 1 |
Grodin, EN | 1 |
Meredith, LR | 1 |
Hurley, B | 1 |
Miotto, K | 1 |
Gillis, AJ | 1 |
Ray, LA | 1 |
Bach, P | 1 |
Tyson, LD | 2 |
Cheng, A | 1 |
Kelleher, C | 1 |
Strathie, K | 1 |
Lovendoski, J | 1 |
Habtemariam, Z | 1 |
Lewis, H | 2 |
Giri, S | 1 |
Sundaram, S | 1 |
Vannier, AGL | 1 |
Shay, JES | 1 |
Fomin, V | 1 |
Patel, SJ | 1 |
Schaefer, E | 1 |
Goodman, RP | 1 |
Luther, J | 1 |
Bauer, MR | 1 |
Hernández, M | 1 |
Kasten, CR | 2 |
Boehm, SL | 3 |
Logge, W | 2 |
Baillie, A | 7 |
Haber, P | 1 |
Towers, E | 2 |
Riordan, BC | 1 |
Morley, K | 3 |
Barrault, C | 4 |
Alqallaf, S | 2 |
Lison, H | 4 |
Lamote-Chaouche, I | 2 |
Bourcier, V | 2 |
Laugier, J | 2 |
Thevenot, T | 2 |
Labarriere, D | 2 |
Ripault, MP | 2 |
Le Gruyer, A | 2 |
Costentin, C | 3 |
Behar, V | 3 |
Hagege, H | 3 |
Jung, C | 2 |
Cadranel, JF | 4 |
Pelz, P | 3 |
Genauck, A | 1 |
Lorenz, RC | 2 |
Wüstenberg, T | 2 |
Wackerhagen, C | 1 |
Charlet, K | 2 |
Gleich, T | 1 |
Geisel, O | 6 |
Heinz, A | 4 |
Müller, CA | 8 |
Beck, A | 3 |
Agabio, R | 8 |
Saulle, R | 2 |
Rösner, S | 2 |
Minozzi, S | 3 |
Ross, H | 1 |
Harries, B | 1 |
Szelest, I | 1 |
Engelbrecht, R | 1 |
Umhau, JC | 1 |
Price, ST | 1 |
Brown, B | 1 |
Hurzeler, T | 1 |
Arunogiri, S | 1 |
Haber, PS | 12 |
Duan, F | 1 |
Zhai, H | 1 |
Liu, C | 1 |
Chang, C | 1 |
Song, S | 1 |
Li, J | 1 |
Cheng, J | 1 |
Yang, S | 1 |
Crunelle, CL | 1 |
Jegham, S | 1 |
Vanderbruggen, N | 1 |
Matthys, F | 1 |
Neven, A | 1 |
Dumont, GJH | 1 |
Liu, J | 1 |
Wang, LN | 1 |
Braillon, A | 7 |
Naudet, F | 7 |
Cristea, IA | 1 |
Lexchin, J | 1 |
Rolland, B | 22 |
Simon, N | 5 |
Franchitto, N | 6 |
Aubin, HJ | 5 |
Garbutt, JC | 8 |
Daeppen, JB | 1 |
van den Brink, W | 6 |
Logge, WB | 4 |
Baillie, AJ | 3 |
Morley, KC | 10 |
Echeverry-Alzate, V | 1 |
Jeanblanc, J | 1 |
Sauton, P | 1 |
Bloch, V | 2 |
Labat, L | 1 |
Soichot, M | 1 |
Vorspan, F | 2 |
Naassila, M | 1 |
Reynoard, J | 1 |
Schmitt, C | 1 |
Torrents, R | 1 |
Paille, F | 5 |
Kent, CN | 1 |
Park, C | 1 |
Lindsley, CW | 1 |
Andrade, C | 1 |
Holtyn, AF | 2 |
Weerts, EM | 2 |
Baldwin, DS | 1 |
Amaro, H | 1 |
Leggio, L | 21 |
Sinclair, JMA | 1 |
Marti-Prats, L | 1 |
Belin-Rauscent, A | 1 |
Fouyssac, M | 1 |
Puaud, M | 1 |
Cocker, PJ | 1 |
Everitt, BJ | 1 |
Belin, D | 1 |
Augier, E | 1 |
Reade, MC | 1 |
Vourc'h, M | 2 |
Garret, C | 1 |
Gacouin, A | 1 |
Lacherade, JC | 1 |
Jonas, M | 1 |
Klouche, K | 1 |
Ferrandiere, M | 1 |
Jaber, S | 1 |
Flet, L | 1 |
Dailly, E | 1 |
Pouplet, C | 1 |
Maamar, A | 1 |
Reignier, J | 1 |
Roquilly, A | 1 |
Feuillet, F | 2 |
Mahe, PJ | 2 |
Asehnoune, K | 2 |
Kampov-Polevoy, AB | 2 |
Pedersen, C | 1 |
Stansbury, M | 1 |
Jordan, R | 1 |
Willing, L | 1 |
Gallop, RJ | 1 |
Litten, RZ | 1 |
Boels, D | 3 |
Victorri-Vigneau, C | 2 |
Grall-Bronnec, M | 2 |
Touré, A | 2 |
Garnier, A | 1 |
Turcant, A | 1 |
Le Roux, G | 3 |
Farokhnia, M | 3 |
Schwandt, ML | 1 |
Lee, MR | 3 |
Bollinger, JW | 1 |
Farinelli, LA | 2 |
Amodio, JP | 1 |
Sewell, L | 1 |
Lionetti, TA | 1 |
Spero, DE | 1 |
Beraha, E | 1 |
Bodewits, P | 2 |
Wiers, R | 1 |
Pignon, B | 2 |
Labreuche, J | 6 |
Auffret, M | 12 |
Gautier, S | 11 |
Deheul, S | 12 |
Simioni, N | 2 |
Cottencin, O | 15 |
Bordet, R | 15 |
Duhamel, A | 5 |
Reynaud, M | 2 |
Trinquet, F | 1 |
Zakine, B | 1 |
Dano, C | 1 |
Dematteis, M | 1 |
Trojak, B | 1 |
Detilleux, M | 1 |
Beraha, EM | 5 |
Salemink, E | 3 |
Goudriaan, AE | 2 |
Wiers, RW | 3 |
Nau, JY | 9 |
Pelissier, F | 4 |
de Haro, L | 3 |
Roudot-Thoraval, F | 1 |
Garioud, A | 2 |
Medmoun, M | 2 |
Pulwermacher, G | 2 |
Kaminski, BJ | 1 |
Owens, L | 3 |
Thompson, A | 3 |
Rose, A | 1 |
Gilmore, I | 1 |
Pirmohamed, M | 2 |
Richardson, P | 2 |
Palpacuer, C | 1 |
Duprez, R | 1 |
Huneau, A | 1 |
Locher, C | 1 |
Boussageon, R | 1 |
Laviolle, B | 1 |
Larabi, IA | 1 |
Fabresse, N | 1 |
Knapp, A | 1 |
Forcet, M | 1 |
Baud, FJ | 1 |
Lorin de la Grandmaison, G | 1 |
Alvarez, JC | 3 |
Léger, M | 1 |
Brunet, M | 2 |
Lerolle, N | 1 |
Antonelli, M | 1 |
Ferrulli, A | 8 |
Sestito, L | 1 |
Vassallo, GA | 1 |
Tarli, C | 1 |
Mosoni, C | 1 |
Rando, MM | 1 |
Mirijello, A | 4 |
Gasbarrini, A | 2 |
Addolorato, G | 19 |
Caous, AS | 2 |
Gaboriau, L | 1 |
Hamel, JF | 1 |
Martinez, L | 1 |
Declèves, X | 1 |
Azuar, J | 1 |
Fortias, M | 1 |
Questel, F | 1 |
Dereux, A | 1 |
Grichy, L | 1 |
Barreteau, H | 1 |
Bellivier, F | 1 |
Lépine, JP | 1 |
Donoghue, K | 1 |
Revol, B | 1 |
Jullian-Desayes, I | 1 |
Bailly, S | 1 |
Mallaret, M | 1 |
Tamisier, R | 1 |
Agier, MS | 1 |
Lador, F | 2 |
Joyeux-Faure, M | 2 |
Pépin, JL | 3 |
Schlemm, L | 1 |
Hellweg, R | 4 |
Wiedemann, K | 2 |
Rose, AK | 1 |
Jones, A | 1 |
Costa, M | 1 |
Carrieri, P | 1 |
Bianchi, PC | 1 |
Carneiro de Oliveira, PE | 1 |
Palombo, P | 1 |
Leão, RM | 1 |
Cogo-Moreira, H | 1 |
Planeta, CDS | 1 |
Cruz, FC | 1 |
Vengeliene, V | 1 |
Takahashi, TT | 1 |
Dravolina, OA | 1 |
Belozertseva, I | 1 |
Zvartau, E | 1 |
Bespalov, AY | 1 |
Spanagel, R | 1 |
Sheskier, MB | 1 |
Le, AN | 1 |
Singley, E | 1 |
Bouhlal, S | 1 |
Ton, T | 1 |
Zhao, Z | 1 |
Fraser, I | 2 |
Furneaux-Bate, A | 1 |
Dore, G | 2 |
Roberts, M | 1 |
Abdalla, A | 1 |
Phung, N | 2 |
Pakri Mohamed, RM | 1 |
Kumar, J | 1 |
Ahmad, SU | 1 |
Mohamed, IN | 1 |
Krediet, E | 1 |
Pierce, M | 1 |
Sutterland, A | 1 |
Luquin, N | 1 |
Trent, RJ | 1 |
Calvo, ME | 1 |
Gunnarsson, T | 1 |
Smith, L | 1 |
Hao, M | 1 |
Chaignot, C | 1 |
Zureik, M | 1 |
Rey, G | 1 |
Dray-Spira, R | 1 |
Coste, J | 1 |
Weill, A | 1 |
Deschaine, SL | 1 |
Sadighi, A | 1 |
Akhlaghi, F | 1 |
Sinclair, JM | 2 |
Caputo, F | 6 |
Chick, JD | 1 |
de La Selle, P | 1 |
Heydtmann, M | 2 |
Jaury, P | 2 |
Lingford-Hughes, AR | 1 |
Pastor, A | 3 |
Paterson, LM | 1 |
Stafford, A | 1 |
de Beaurepaire, R | 1 |
Wernecke, KD | 2 |
Morris, RW | 1 |
Castrén, S | 1 |
Mäkelä, N | 1 |
Alho, H | 1 |
Rombouts, SA | 1 |
Béhal, H | 1 |
Jouanjus, E | 2 |
Lloyd-Jones, M | 1 |
Currie, J | 2 |
D'Angelo, C | 3 |
Vassallo, G | 1 |
Cossari, A | 1 |
Gasbarrini, G | 8 |
Landolfi, R | 1 |
Agnes, S | 1 |
Leung, S | 2 |
Marsot, A | 1 |
Imbert, B | 2 |
Grassin-Delyle, S | 1 |
Jaquet, I | 1 |
Lançon, C | 1 |
Pommier, P | 1 |
Debaty, G | 1 |
Bartoli, M | 1 |
Viglino, D | 1 |
Carpentier, F | 1 |
Danel, V | 1 |
Maxime, M | 1 |
Dupouy, J | 1 |
Fournier, JP | 1 |
Palmaro, A | 1 |
Poutrain, JC | 1 |
Oustric, S | 1 |
Lapeyre-Mestre, M | 2 |
Jaillette, E | 1 |
Carton, L | 2 |
Bence, C | 2 |
Saulnier, F | 1 |
Lecomte, L | 1 |
Loche, V | 1 |
Hennaux, C | 1 |
Fleury, B | 1 |
Benyamina, A | 2 |
Zywiak, WH | 2 |
Edwards, SM | 1 |
Tidey, JW | 1 |
Swift, RM | 6 |
Kenna, GA | 6 |
Smadja, J | 1 |
Paradis, M | 1 |
Pape, E | 1 |
Roman, E | 1 |
Scala-Bertola, J | 1 |
Thivilier, C | 1 |
Javot, L | 1 |
Saint-Marcoux, F | 1 |
Jouzeau, JY | 1 |
Gambier, N | 1 |
Valin, T | 2 |
Langlois, C | 1 |
Danel, T | 1 |
Arbouw, ME | 1 |
Hoge, HL | 1 |
Meulenbelt, J | 1 |
Jansman, FG | 1 |
Blasingame, SN | 1 |
Ponizovsky, AM | 1 |
Rosca, P | 1 |
Aronovich, E | 1 |
Weizman, A | 1 |
Grinshpoon, A | 1 |
Béné, J | 1 |
Soyka, M | 1 |
Lieb, M | 1 |
Besson, J | 1 |
Khazaal, Y | 1 |
Tomei, A | 1 |
Grivel, J | 1 |
Zullino, D | 1 |
Borro, P | 1 |
Leone, S | 1 |
Testino, G | 1 |
Rigal, L | 1 |
Legay Hoang, L | 1 |
Alexandre-Dubroeucq, C | 1 |
Pinot, J | 1 |
Le Jeunne, C | 1 |
Higl, V | 1 |
Krüger, J | 1 |
Stickel, A | 1 |
Holla, B | 1 |
Gowda, GS | 1 |
Prabhu, L | 1 |
Baby, S | 1 |
Viswanath, B | 1 |
Chand, P | 1 |
Murthy, P | 1 |
Krupitsky, EM | 2 |
Rybakova, KV | 1 |
Kiselev, AS | 1 |
Alexeeva, YV | 1 |
Berntsev, VA | 1 |
Chekhlaty, EI | 1 |
Zubova, EY | 1 |
Popov, YV | 1 |
Neznanov, NG | 1 |
Perogamvros, L | 1 |
Thorens, G | 1 |
Mégevand, P | 1 |
Claudel, E | 1 |
Espa, F | 1 |
Besson, M | 1 |
Cervena, K | 1 |
Janssens, JP | 1 |
Weibel, S | 1 |
Lalanne, L | 1 |
Riegert, M | 1 |
Bertschy, G | 1 |
Preda, C | 1 |
Deken, V | 1 |
Olivier, PY | 1 |
Gentina, T | 1 |
Launois, SH | 1 |
d'Ortho, MP | 1 |
Gagnadoux, F | 1 |
Journiac, K | 1 |
Pascuttini, F | 1 |
Touzeau, D | 1 |
Rivollier, F | 1 |
Masson, M | 1 |
Bole, R | 1 |
Indla, V | 1 |
Awachar, R | 1 |
Reddy, IR | 1 |
de Witte, LD | 1 |
Dekker, D | 1 |
Veraart, J | 1 |
Kromkamp, M | 1 |
Kaasjager, K | 1 |
Vinkers, CH | 1 |
Sebille, V | 1 |
Gupta, M | 1 |
Verma, P | 1 |
Rastogi, R | 1 |
Arora, S | 1 |
Elwadhi, D | 1 |
Bakker, A | 1 |
de Jong, D | 1 |
Smits, N | 1 |
Zwart, JW | 1 |
Geest, DV | 1 |
Schiphof, T | 1 |
Defourny, H | 1 |
van Tricht, M | 1 |
Dib, M | 1 |
Kemkem, A | 1 |
Grit, I | 1 |
Drelon, M | 1 |
Cabe, N | 1 |
Vabret, F | 1 |
Guillin, O | 1 |
Baguet, A | 1 |
Masquelier, C | 1 |
Dervaux, A | 1 |
Jardri, R | 1 |
Azevedo, CA | 1 |
Mammis, A | 1 |
Cardona, F | 1 |
Picot, C | 1 |
Puskarczyk, E | 1 |
Sapori, JM | 1 |
Tournoud, C | 1 |
Hauser, P | 1 |
Fuller, B | 1 |
Ho, SB | 1 |
Thuras, P | 1 |
Kern, S | 1 |
Dieperink, E | 1 |
Goh, ET | 1 |
Morgan, MY | 1 |
Shah, R | 1 |
Singla, H | 1 |
Maccioni, P | 2 |
Fantini, N | 1 |
Froestl, W | 1 |
Carai, MA | 4 |
Gessa, GL | 6 |
Colombo, G | 7 |
Cardone, S | 5 |
Malandrino, N | 2 |
Vonghia, L | 2 |
Miceli, A | 3 |
Capristo, E | 3 |
Hadengue, A | 1 |
Gache, P | 2 |
Kiefer, F | 1 |
Johnson, BA | 2 |
Gallop, R | 1 |
Kalka-Juhl, L | 1 |
Flannery, BA | 2 |
Soufia, M | 1 |
Plaze, M | 1 |
Gueguen, B | 1 |
Demigneux, G | 1 |
Olié, JP | 1 |
Gaillard, R | 1 |
Saddichha, S | 1 |
Jayaram, N | 1 |
Manjunatha, N | 1 |
Benegal, V | 1 |
Ameisen, O | 3 |
Nesci, A | 1 |
Canestrelli, B | 1 |
Monteleone, P | 1 |
Enserink, M | 1 |
Macaigne, G | 1 |
Champagnon, N | 1 |
Harnois, F | 1 |
Cheiab, S | 1 |
Chayette, C | 1 |
Amato, L | 1 |
Davoli, M | 1 |
Lyon, JE | 1 |
Khan, RA | 1 |
Gessert, CE | 1 |
Larson, PM | 1 |
Renier, CM | 1 |
Helland, A | 1 |
Bramness, JG | 1 |
Muzyk, AJ | 1 |
Rivelli, SK | 1 |
Gagliardi, JP | 1 |
Zambon, A | 2 |
Jones, DM | 1 |
Le Strat, Y | 1 |
Gorsane, MA | 1 |
Kebir, O | 1 |
Hache, G | 1 |
Blecha, L | 1 |
Howland, RH | 1 |
Peters, S | 1 |
Slattery, DA | 1 |
Flor, PJ | 1 |
Neumann, ID | 1 |
Reber, SO | 1 |
McGeary, JE | 1 |
Edwards, S | 1 |
Fricchione, SR | 1 |
Shoaff, JR | 1 |
Serra, S | 2 |
Brunetti, G | 1 |
Vacca, G | 2 |
McGregor, IS | 1 |
Gallate, JE | 1 |
Kaplan, GB | 1 |
McRoberts, RL | 1 |
Smokler, HJ | 1 |
Pibiri, F | 1 |
Cody, MW | 1 |
Renn, W | 1 |
Grace, K | 1 |
Osborne, M | 1 |
Crosby, K | 1 |
Morreale, M | 1 |
Trivette, A | 1 |
Abenavoli, L | 2 |
Heilig, M | 1 |
Egli, M | 1 |
Walker, BM | 1 |
Koob, GF | 1 |
Marras, P | 1 |
Carpiniello, B | 1 |
Moore, EM | 1 |
Serio, KM | 1 |
Goldfarb, KJ | 1 |
Stepanovska, S | 1 |
Linsenbardt, DN | 1 |
Vignoli, T | 1 |
Francini, S | 1 |
Stoppo, M | 1 |
Bernardi, M | 1 |
Stallings, W | 1 |
Schrader, S | 1 |
Ozsoy, S | 1 |
Esel, E | 1 |
Turan, T | 1 |
Kula, M | 1 |
Flannery, B | 1 |
Quintanilla, ME | 1 |
Perez, E | 1 |
Tampier, L | 1 |
Tarika, JS | 1 |
Winger, G | 1 |
Krupitskiĭ, EM | 2 |
Burakov, AM | 3 |
Ivanov, VB | 2 |
Karandashova, GF | 1 |
Lapin, IP | 2 |
Grinenko, AIa | 2 |
Borodkin, IuS | 2 |
Krandashova, GF | 1 |
Vescovi, PP | 2 |
Volpi, R | 1 |
Coiro, V | 2 |
Lobina, C | 1 |
Pani, M | 1 |
Reali, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial[NCT02723383] | Phase 3 | 314 participants (Actual) | Interventional | 2016-06-27 | Completed | ||
A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics[NCT01751386] | Phase 2 | 39 participants (Actual) | Interventional | 2012-12-03 | Completed | ||
Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease[NCT01711125] | Phase 3 | 104 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
Modification of Pavlovian and Instrumental Learning in Human Addiction[NCT04032587] | 80 participants (Anticipated) | Interventional | 2019-10-01 | Recruiting | |||
Baclofen for the Treatment of Alcohol Dependence - BACLAD[NCT01266655] | Phase 2/Phase 3 | 56 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking[NCT01076283] | Phase 2 | 14 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
Effects of Ghrelin on Alcohol Cue Reactivity and Craving[NCT01190085] | 45 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
A Novel Compound for Alcoholism Treatment: A Translational Strategy[NCT02039349] | Phase 1 | 14 participants (Actual) | Interventional | 2014-01-03 | Completed | ||
Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers[NCT01779024] | Phase 2 | 17 participants (Actual) | Interventional | 2012-12-13 | Completed | ||
Prospective Assessment of Valproate on Ethanol Withdrawal[NCT03235531] | Phase 4 | 210 participants (Anticipated) | Interventional | 2017-07-11 | Recruiting | ||
Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study[NCT00525252] | Phase 1/Phase 2 | 86 participants | Interventional | 2003-02-28 | Completed | ||
Spironolactone in Alcohol Use Disorder (SAUD): A Double-Blind, Placebo-Controlled, Ascending Dose, Phase 1b Study[NCT05807139] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-03 | Recruiting | ||
Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial[NCT00597701] | 79 participants (Actual) | Interventional | 2003-04-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL. (NCT01751386)
Timeframe: 2 hours
Intervention | mini-drinks (Mean) |
---|---|
Baclofen | 4.11 |
Placebo | 4.5 |
"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
Intervention | standard drinking units (Mean) |
---|---|
Baclofen | 0.17 |
Cyproheptadine | 1.43 |
"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
Intervention | units on a scale (Mean) |
---|---|
Baclofen | 22.5 |
Cyproheptadine | 19.4 |
"Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Visual Analogue Scale (A-VAS)].~The A-VAS was rated on 11-point anchored Likert-type scales, where 0 is the minimum score (no craving) and 11 is the maximum score (highest craving intensity). The change in the A-VAS score (deltaA-VAS) was used to indicate decrease (-d) or increase (+d) in craving intensity." (NCT01190085)
Timeframe: approximately 30 minutes after drug administration
Intervention | units on a scale (Mean) |
---|---|
Ghrelin (1 Microg/kg) | 1.95 |
Ghrelin (3 Microg/kg) | 2.66 |
Saline Solution | 4.29 |
Whether ghrelin intravenous (i.v.), as compared to saline i.v., does not significantly increase Adverse Events (AEs). (NCT01190085)
Timeframe: participants will be followed after the cue-reactivity experiment, an expected average of 7 days
Intervention | participants (Number) |
---|---|
Ghrelin (1 Microg/kg) | 11 |
Ghrelin (3 Microg/kg) | 12 |
Saline Solution | 15 |
Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of psychophysiological responses, namely salivation changes. (NCT01190085)
Timeframe: approximately 30 minutes after drug administration
Intervention | gram (Mean) |
---|---|
Ghrelin (1 Microg/kg) | 1.8 |
Ghrelin (3 Microg/kg) | 1.9 |
Saline Solution | 3.2 |
The total number of alcohol infusions self-administered. (NCT01779024)
Timeframe: 120 minutes after the start of the infusion
Intervention | Number of alcohol infusions (Mean) |
---|---|
Ghrelin | 10.45 |
Placebo | 8.80 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 11.6932 |
Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 8.7646 |
Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 11.4075 |
Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 9.6218 |
Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 13.9789 |
Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 9.9075 |
Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 9.6218 |
Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 8.9075 |
Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 12.1376 |
Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 9.7805 |
Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 11.7091 |
Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 11.3519 |
Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 14.1376 |
Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 11.2805 |
Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 12.2091 |
Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 13.1376 |
Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 12.977 |
Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 15.1645 |
Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 18.4145 |
Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 20.352 |
Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 13.7895 |
Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.8582 |
Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.4777 |
Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.5443 |
Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.011 |
Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.611 |
Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 5.3112 |
Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.2231 |
Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 5.2365 |
Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.6777 |
Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.6078 |
Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 10.002 |
Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.3187 |
Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.6521 |
Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 8.0521 |
Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.0521 |
Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 4.8092 |
Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.149 |
Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 4.8071 |
Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 8.2521 |
Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.6366 |
Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 9.5572 |
Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.7 |
Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 5.7 |
Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 6.2715 |
Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 5.2715 |
Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 4.6286 |
Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 3.6083 |
Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 3.7666 |
Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 7.9858 |
Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
Intervention | Units on a scale (Least Squares Mean) |
---|---|
GSK561679 | 8.1286 |
Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | Units on a scale (Mean) |
---|---|
Pexacerfont | 16.6 |
Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | Units on a scale (Mean) |
---|---|
Pexacerfont | 12.7 |
Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 16.5 |
Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 15 |
Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 18.7 |
Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 13.7 |
Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 13.5 |
Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 13.7 |
Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 16.8 |
Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 12.9 |
Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 15.3 |
Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 14.9 |
Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 17.8 |
Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 14.3 |
Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | units on a scale (Mean) |
---|---|
Pexacerfont | 14.9 |
Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
Intervention | Units on a scale (Mean) |
---|---|
Pexacerfont | 14.6 |
Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
Intervention | Units on a scale (Mean) |
---|---|
Acamprosate | 3.460 |
Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
Intervention | Units on a scale (Mean) |
---|---|
Acamprosate | 1.704 |
Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
Intervention | Units on a scale (Mean) |
---|---|
Acamprosate | 3.613 |
Placebo | 3.606 |
In acutely-withdrawing alcoholic patients treated with either baclofen or placebo, symptom-driven benzodiazepine doses were assessed for the 72 hours following the first Clinical Institute Withdrawal Assessment (CIWA) score of 11 or greater. (NCT00597701)
Timeframe: From eligibility for randomization (Clinical Institute Withdrawal Assessment [CIWA] score of at least 11) until 72 hours of observation had been completed.
Intervention | mg of benzodiazepine per 8 hours (Mean) |
---|---|
Baclofen | 14.1 |
Placebo | 124.4 |
39 reviews available for baclofen and Alcohol Abuse
Article | Year |
---|---|
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Humans; Naltrexone; Topiramate | 2022 |
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans | 2022 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Adult; Alcohol Drinking; Alcoholism; Baclofen; Chronic Disease; Female; Humans; Male; M | 2023 |
Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Humans; Liver Diseases | 2023 |
[The efficacy of baclofen in alcohol dependence].
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Treatment Outcome | 2019 |
Baclofen for alcohol withdrawal.
Topics: Alcoholism; Baclofen; Craving; GABA Agonists; Humans; Randomized Controlled Trials as Topic; Substan | 2019 |
Toxicological considerations in the prescription of baclofen for the treatment of substance use disorders.
Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans; Off-Label | 2020 |
Classics in Chemical Neuroscience: Baclofen.
Topics: Alcoholism; Baclofen; Brain; gamma-Aminobutyric Acid; Humans; Neurosciences; Receptors, GABA-B | 2020 |
Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption.
Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Meta-Analysis as Topic | 2020 |
The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Humans | 2021 |
Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder.
Topics: Acetamides; Alcoholism; Animals; Baclofen; Bacterial Proteins; GABA-B Receptor Agonists; Mice; Rats; | 2021 |
GABA
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Receptors, GABA-B; Substance Withdrawal Synd | 2022 |
Systematic review: Baclofen dosing protocols for alcohol use disorders used in observational studies.
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Observational Studies as Topic | 2017 |
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topirama | 2018 |
Alcohol addiction - the safety of available approved treatment options.
Topics: Alcohol Deterrents; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Drug Approval; Europe; F | 2018 |
Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis.
Topics: Affect; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Depression; GA | 2018 |
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; | 2018 |
Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis.
Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans | 2018 |
Baclofen for alcohol use disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Craving; Depression; Female | 2018 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapent | 2019 |
Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2013 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; | 2013 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Na | 2015 |
Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment.
Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Dose-Response Relationship, Drug; GABA-B Recepto | 2016 |
Neuromodulation Therapies for Alcohol Addiction: A Literature Review.
Topics: Alcoholism; Animals; Baclofen; Deep Brain Stimulation; Humans; Neurotransmitter Agents; Transcranial | 2018 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Huma | 2017 |
The state of pharmacotherapy for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Delayed-Action Preparations | 2009 |
Role of the GABA(B) receptor in alcohol-seeking and drinking behavior.
Topics: Alcohol Drinking; Alcoholism; Allosteric Regulation; Animals; Baclofen; Cyclopentanes; GABA Modulato | 2009 |
Effectiveness and safety of baclofen in the treatment of alcohol dependent patients.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Baclofen; Brain; Brain Chemistry; Cl | 2010 |
Safety and efficacy of baclofen in the treatment of alcohol-dependent patients.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Re | 2010 |
Medication treatment of different types of alcoholism.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Chronic Disease; Depressive Disorder; Female; | 2010 |
Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome.
Topics: Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Baclofen; Benzodiazepines; Ethanol; Humans | 2011 |
[Baclofen: the new miracle cure for alcoholism?].
Topics: Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Humans; R | 2011 |
Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence.
Topics: Alcoholism; Animals; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans; Randomized | 2012 |
Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates.
Topics: Alcoholism; Animals; Baclofen; Behavior, Addictive; Clinical Trials as Topic; Disease Management; Di | 2012 |
Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Clinical Trials as Topic; Ethanol; GABA Agonists; H | 2004 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Baclofen: a new drug for the treatment of alcohol dependence.
Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Secondary Prevention | 2006 |
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Topics: Acamprosate; Alcoholism; Animals; Baclofen; Disulfiram; Fructose; Humans; Naltrexone; Ondansetron; R | 2008 |
42 trials available for baclofen and Alcohol Abuse
Article | Year |
---|---|
Sex differences in the interrelations between stress, craving and alcohol consumption across individuals and time during baclofen treatment for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Craving; Female; Humans; Male; Sex Characteristics | 2023 |
Effects of baclofen on insular gain anticipation in alcohol-dependent patients - a randomized, placebo-controlled, pharmaco-fMRI pilot trial.
Topics: Alcoholism; Anticipation, Psychological; Baclofen; Central Nervous System Depressants; Ethanol; Huma | 2023 |
Hypothalamic-pituitary-adrenocortical response in alcohol-dependent patients during baclofen treatment and association with clinical outcome: Preliminary results.
Topics: Alcoholism; Baclofen; Ethanol; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Pituitary-Adr | 2023 |
Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial.
Topics: Alcoholism; Baclofen; Benzodiazepines; Diazepam; Double-Blind Method; Humans; Single-Blind Method; S | 2023 |
Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals.
Topics: Alcoholism; Baclofen; Craving; Cues; Dose-Response Relationship, Drug; Female; GABA-B Receptor Agoni | 2020 |
Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial.
Topics: Adult; Aged; Alcohol-Induced Disorders; Alcoholism; Baclofen; Double-Blind Method; Female; GABA-B Re | 2021 |
Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; Humans; Male; Middle Aged; Treatment Outcome | 2021 |
Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Biobehavioral Sciences; Craving; Double-Blin | 2017 |
A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients-The ALPADIR Study.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Craving; Double-Blind Method; Female; GABA-B Receptor | 2017 |
Hypothalamic-Pituitary-Adrenocortical Axis Activity in Alcohol-Dependent Patients During Treatment with High-Dose Baclofen.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Alcoholism; Baclofen; Double-Blind Method; Fem | 2019 |
Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.
Topics: Adult; Alcohol Deterrents; Alcoholism; Ambulatory Care; Baclofen; Biomarkers; Double-Blind Method; F | 2018 |
Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Alcoholism; Baclofen; Double-Blind Method; Female; GABA-B Receptor Agonists; Humans; Liver Di | 2018 |
Can baclofen change alcohol-related cognitive biases and what is the role of anxiety herein?
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Anxiety Disorders; Attentional Bias; | 2018 |
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum | 2018 |
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum | 2018 |
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum | 2018 |
Effects of high-dose baclofen on cue reactivity in alcohol dependence: A randomized, placebo-controlled pharmaco-fMRI study.
Topics: Adult; Alcoholism; Baclofen; Brain; Cues; Double-Blind Method; Female; GABA-B Receptor Agonists; Hum | 2018 |
A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation.
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Laboratories; Receptors, GABA-B | 2021 |
Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease.
Topics: Adult; Aged; Alcoholism; Baclofen; Cues; Double-Blind Method; Executive Function; Female; GABA-B Rec | 2019 |
Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen.
Topics: Acylation; Adult; Alcoholism; Baclofen; Biomarkers; Double-Blind Method; Female; GABA-B Receptor Ago | 2019 |
Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
Topics: Adult; Alcoholism; Baclofen; Brain; Craving; Cues; Double-Blind Method; Female; Humans; Magnetic Res | 2021 |
Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; Dose-Response Rel | 2019 |
The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Clinical Protocols; Double-Blind Method; Drug Administration | 2013 |
A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2015 |
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.
Topics: Adult; Alcohol Abstinence; Alcoholism; Anxiety; Baclofen; Double-Blind Method; Female; GABA-B Recept | 2014 |
Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up.
Topics: Adult; Alcoholism; Baclofen; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studi | 2015 |
High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial.
Topics: Adult; Alcohol Abstinence; Alcohol Deterrents; Alcoholism; Baclofen; Double-Blind Method; Female; Fo | 2015 |
[Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence].
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind M | 2015 |
Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen.
Topics: Adult; Alcoholism; Baclofen; Brain-Derived Neurotrophic Factor; Double-Blind Method; Female; GABA-B | 2016 |
Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Clinical Protocols; Double-Blind Method; Female; Huma | 2016 |
Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Craving; GABA-B Receptor | 2017 |
Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial.
Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Double-Blind Method | 2016 |
The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up Studies; GABA-B Receptor Agonists; Hepa | 2017 |
Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; Depression; Double-Blind Method; | 2010 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Case-Control Studies; Drug-Seeking Behavior; Female; | 2012 |
Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Alcoholism; Baclofen; Double-Blind Method; Female; Humans; Male; Middle | 2011 |
Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection.
Topics: Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; | 2012 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
A human laboratory pilot study with baclofen in alcoholic individuals.
Topics: Adult; Alcohol Drinking; Alcoholics; Alcoholism; Baclofen; Double-Blind Method; Female; Follow-Up St | 2013 |
Baclofen for alcohol dependence: a preliminary open-label study.
Topics: Adult; Alcoholism; Baclofen; Female; Humans; Male; Middle Aged | 2004 |
Baclofen for alcoholism.
Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Liver Cirrhosis, Alcoholic; Patient Selection; Temperan | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study.
Topics: Alcoholism; Aldosterone; Baclofen; Behavior, Addictive; Counseling; Female; Humans; Longitudinal Stu | 2008 |
[The use of baclofen for treating affective disorders in alcoholism].
Topics: Adult; Alcoholism; Amitriptyline; Baclofen; Diazepam; Drug Evaluation; Humans; Ligands; Mood Disorde | 1994 |
Baclofen administration for the treatment of affective disorders in alcoholic patients.
Topics: Administration, Oral; Adult; Alcoholism; Amitriptyline; Anxiety Disorders; Baclofen; Blood Platelets | 1993 |
[Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients].
Topics: Alcoholism; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Baclofen; Color Pe | 1995 |
136 other studies available for baclofen and Alcohol Abuse
Article | Year |
---|---|
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Retrospective Studies | 2022 |
Acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nal | 2022 |
Systemic administration of racemic baclofen reduces both acquisition and maintenance of alcohol consumption in male and female mice.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Ethanol; Female; GABA-B Receptor Agonists; Male; Mi | 2022 |
Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?'
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Incorporating ondansetron and baclofen in alcohol use disorder treatment.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Ondansetron | 2023 |
Baclofen for the Treatment of Alcohol Use Disorder.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans | 2023 |
Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?
Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; History, 21st Century; Humans | 2020 |
France Grants an Approval to Baclofen for Alcohol Dependence.
Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; History, 21st Century; Humans | 2020 |
Approval of Baclofen for Alcohol Use Disorders in France: A Perspective From the United States.
Topics: Alcoholism; Baclofen; Drug Approval; Female; France; GABA-B Receptor Agonists; Humans; Male; Meta-An | 2020 |
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2019 |
Baclofen: A Game Changer in the Treatment of Alcohol Dependence.
Topics: Alcoholism; Baclofen; Drug Approval; France; GABA-B Receptor Agonists; Health Services Accessibility | 2020 |
Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor A | 2021 |
[Medical management of alcohol use disorders].
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Humans | 2019 |
GABA
Topics: Alcoholism; Allosteric Regulation; Animals; Baclofen; Rats; Receptors, GABA-B; Substance Withdrawal | 2022 |
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit.
Topics: Alcohol Drinking; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2021 |
Baclofen decreases compulsive alcohol drinking in rats characterized by reduced levels of GAT-3 in the central amygdala.
Topics: Alcoholism; Animals; Baclofen; Central Amygdaloid Nucleus; Compulsive Behavior; Conditioning, Operan | 2021 |
Baclofen to Prevent Agitation Caused by Alcohol Withdrawal in the ICU.
Topics: Alcoholism; Baclofen; Humans; Intensive Care Units; Respiration, Artificial; Substance Withdrawal Sy | 2021 |
[Baclofen in the treatment of alcohol addiction : a French saga].
Topics: Alcoholism; Baclofen; France; Humans; Medicine; Off-Label Use | 2021 |
The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter.
Topics: Alcoholism; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Receptors, GABA-B | 2021 |
Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning.
Topics: Adult; Alcoholism; Baclofen; Cardiovascular Diseases; Craving; Female; France; GABA-B Receptor Agoni | 2017 |
Speaking fluently with baclofen?
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Anxiety; Baclofen; GABA-B Receptor Agonists; Human | 2017 |
The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug; | 2017 |
Baclofen and alcohol use disorders: From miracle to mirage.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2017 |
Response to "Baclofen and alcohol use disorders: From miracle to mirage".
Topics: Alcohol-Related Disorders; Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans | 2017 |
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Treatment Outcome | 2016 |
Severity of Baclofen Self-Poisoning Linked to Psychiatric Co-morbidity in Alcohol-Dependent Patients: Better Measurement of Risk and Benefit.
Topics: Alcoholism; Baclofen; Comorbidity; Ethanol; Humans; Risk | 2017 |
Topics: Alcoholism; Baclofen; Electronic Nicotine Delivery Systems; France; Humans | 2016 |
Topics: Alcoholism; Baclofen; Food Labeling; France; Health Services Accessibility; Humans | 2017 |
One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Female; France; GABA-B Receptor A | 2017 |
Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Animals; Baclofen; Disease Models, Animal; GABA-B | 2017 |
A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic.
Topics: Adult; Aged; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Bilirubin; Biomarkers; Coho | 2017 |
Baclofen and the "first do not harm" motto: a new French paradox?
Topics: Alcoholism; Baclofen; Ethanol; Humans; Poison Control Centers | 2018 |
Focusing solely on the effect of the medication without taking a holistic view of the patient does not seem very constructive.
Topics: Alcoholism; Baclofen; Ethanol; Humans; Language; Poison Control Centers | 2018 |
LC-MS/MS method for quantification of baclofen in hair: A useful tool to assess compliance in alcohol dependent patients?
Topics: Alcoholism; Baclofen; Biomarkers; Chromatography, Liquid; Drug Monitoring; Ethanol; Female; GABA-B R | 2018 |
Baclofen Self-Poisoning in the Era of Changing Indication: Multicentric Reports to a French Poison Control Centre.
Topics: Adult; Alcoholism; Baclofen; Drug Overdose; Female; France; Humans; Male; Middle Aged; Muscle Relaxa | 2017 |
On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies.
Topics: Alcoholism; Attitude of Health Personnel; Baclofen; Community Pharmacy Services; Drug and Narcotic C | 2018 |
Response to the Letter to the Editor Regarding "Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning."
Topics: Alcohol Drinking; Alcoholism; Baclofen; Ethanol; Humans; Risk | 2018 |
An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with vs. without chronic pretreatment with high-dosage baclofen.
Topics: Administration, Oral; Adult; Alcohol Drinking; Alcoholism; Baclofen; Diazepam; Female; GABA Modulato | 2018 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Netwo | 2018 |
Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Alcoholism; Apnea; Baclofen; Database | 2018 |
The need for patient-tailored dosing of baclofen in future clinical trials
Topics: Alcoholism; Baclofen; Humans; Injections, Spinal; Muscle Relaxants, Central | 2018 |
Functional inactivation of the orbitofrontal cortex disrupts context-induced reinstatement of alcohol seeking in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Conditioning, Operant; Drug-Seeking Behavior; Femal | 2018 |
An observational study of benzodiazepine prescription during inpatient alcohol detoxification for patients with versus without chronic pretreatment with high dosage baclofen.
Topics: Alcoholism; Baclofen; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Inpatients | 2018 |
Efficacy and side effects of baclofen and the novel GABA
Topics: Alcoholism; Allosteric Regulation; Animals; Baclofen; Behavior, Addictive; Cocaine; Cocaine-Related | 2018 |
Moderation of baclofen response by a GABA
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male; Middl | 2018 |
Delirium tremens in an AUD patient after an intrathecal baclofen pump induced total alcohol abstinence.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Diazepam; H | 2018 |
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofe | 2018 |
Baclofen and alcohol in France.
Topics: Alcoholism; Baclofen; Ethanol; France; Humans | 2018 |
Baclofen and alcohol in France - Authors' reply.
Topics: Alcoholism; Baclofen; Ethanol; France; Humans | 2018 |
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.
Topics: Alcoholism; Baclofen; Humans | 2018 |
Letter to the Editor: No Baclofen for Alcohol Use Disorders Even More When Liver Disease Is Serious!
Topics: Alcoholism; Baclofen; End Stage Liver Disease; Humans; Liver Diseases, Alcoholic | 2019 |
A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Baclofen; Data Mining; Databases, | 2019 |
Baclofen for alcohol-dependence: anticraving or partial substitution?
Topics: Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male | 2013 |
Reply to Dr Rolland et al re: "Baclofen for alcohol-dependence: anticraving or partial substitution?".
Topics: Alcoholism; Baclofen; Female; GABA-B Receptor Agonists; Humans; Male | 2013 |
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center.
Topics: Adult; Aged; Alcohol Abstinence; Alcoholics; Alcoholism; Baclofen; Female; Follow-Up Studies; Humans | 2013 |
[Alcoholism and baclofen: a strange French affair].
Topics: Alcoholism; Baclofen; Ethanol; France; Humans | 2013 |
[The death of Dr. Olivier Ameisen, promoter of baclofen for alcoholism].
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Physicians; Self Medication | 2013 |
High variability in the exposure of baclofen in alcohol-dependent patients.
Topics: Adult; Aged; Alcoholism; Algorithms; Area Under Curve; Baclofen; Dose-Response Relationship, Drug; F | 2014 |
Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study.
Topics: Adult; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Drug Overdose; Endpoint Determination | 2014 |
Baclofen for alcohol dependence in France: incidence of treated patients and prescription patterns--a cohort study.
Topics: Alcoholism; Baclofen; Dantrolene; Europe; Female; France; Hospitalization; Humans; Incidence; Male; | 2014 |
Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Conf | 2014 |
[Involvement of pharmacists in systems for supervising off-label medications: example of the CAMTEA system for the prescription of baclofen in alcohol use disorder in Northern France].
Topics: Alcoholism; Baclofen; Directive Counseling; Feasibility Studies; France; Humans; Off-Label Use; Pati | 2014 |
Severe tinnitus induced by off-label baclofen.
Topics: Alcoholism; Baclofen; Dose-Response Relationship, Drug; Female; GABA-B Receptor Agonists; Humans; Ma | 2014 |
[Alcohol and baclofen: France will finally experiment on a large scale].
Topics: Alcoholic Beverages; Alcoholism; Baclofen; Dose-Response Relationship, Drug; France; Humans; Muscle | 2014 |
Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.
Topics: Alcoholism; Baclofen; Data Collection; Dose-Response Relationship, Drug; Drug Prescriptions; France; | 2014 |
[Addictions, alcoholism and baclofen: latest French news].
Topics: Alcoholism; Baclofen; France; Humans; Off-Label Use; Practice Patterns, Physicians'; Reimbursement M | 2014 |
[Baclofen: Innovative treatment or French controversy?].
Topics: Alcoholism; Baclofen; Behavior; Dissent and Disputes; Drug Repositioning; France; History, 21st Cent | 2015 |
Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen?
Topics: Alcoholism; Antipruritics; Baclofen; Central Nervous System Depressants; Drug Overdose; Ethanol; Fat | 2014 |
Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Borderline Personality Disorder; | 2015 |
Increase of baclofen intoxications: risks involved and management.
Topics: Alcoholism; Baclofen; Diagnosis, Dual (Psychiatry); Female; GABA-B Receptor Agonists; Humans; Middle | 2014 |
Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption.
Topics: Alcoholism; Animals; Baclofen; Binge Drinking; Disease Models, Animal; Dose-Response Relationship, D | 2015 |
[Baclofen: don't forget the initial therapeutic indications].
Topics: Aged; Alcoholism; Arthralgia; Baclofen; Humans; Male; Substance Withdrawal Syndrome | 2015 |
Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France.
Topics: Alcoholism; Attitude of Health Personnel; Baclofen; Community Pharmacy Services; France; GABA-B Rece | 2015 |
[Addiction].
Topics: Alcoholism; Baclofen; Cell Phone; Empathy; GABA-B Receptor Agonists; Humans; Substance-Related Disor | 2015 |
High-dose baclofen: withdrawal syndrome following abrupt discontinuation.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcoholism; Baclofen; Drug Administration Schedule; GABA-B Rec | 2014 |
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug C | 2016 |
Tolerability of High-dose Baclofen in the Treatment of Patients with Alcohol Disorders: A Retrospective Study.
Topics: Adult; Alcoholism; Baclofen; Depression; Dose-Response Relationship, Drug; Female; GABA-B Receptor A | 2015 |
Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Baclofen; Central Nervous System Depressants; Dose | 2015 |
Anticraving Effect of Baclofen in Alcohol-Dependent Patients.
Topics: Adult; Aged; Alcoholism; Baclofen; Craving; Female; GABA-B Receptor Agonists; Humans; Male; Middle A | 2015 |
High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern.
Topics: Adult; Alcoholism; Baclofen; Drug Overdose; Humans; Male; Muscle Relaxants, Central; Suicide, Attemp | 2015 |
Baclofen-Associated Onset of Central Sleep Apnea in Alcohol Use Disorder: A Case Report.
Topics: Alcoholism; Baclofen; Continuous Positive Airway Pressure; GABA-B Receptor Agonists; Humans; Male; M | 2015 |
Efficacy of High-Dose Baclofen for Alcohol Use Disorder and Comorbid Bulimia: A Case Report.
Topics: Adult; Alcoholism; Baclofen; Bulimia Nervosa; Craving; Diagnosis, Dual (Psychiatry); Female; Humans; | 2015 |
[Baclofen: when does one know the scientific truth about its effectiveness in alcoholic disease?].
Topics: Alcohol Deterrents; Alcoholism; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans; | 2015 |
Characteristics of Patients with Alcohol Dependence Seeking Baclofen Treatment in France: A Two-Centre Comparative Cohort Study.
Topics: Alcoholism; Baclofen; Female; France; GABA-B Receptor Agonists; Humans; Male; Middle Aged; Patient A | 2016 |
Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series.
Topics: Aged; Alcoholism; Baclofen; Central Nervous System Depressants; Ethanol; Humans; Male; Middle Aged; | 2016 |
[The baclofene saga and the paradigm shift in alcohol addiction treatment].
Topics: Alcoholism; Baclofen; GABA-B Receptor Agonists; Humans; Practice Guidelines as Topic; Treatment Outc | 2016 |
[Manic symptoms induced by high doses of baclofen: A case report].
Topics: Adult; Alcoholism; Antimanic Agents; Baclofen; Bipolar Disorder; Bromazepam; GABA Agonists; Humans; | 2016 |
BACLOFEN-INDUCED PSYCHOSIS IN A PATIENT WITH ALCOHOL DEPENDENCE.
Topics: Adult; Alcohol Deterrents; Alcoholism; Baclofen; Diagnosis, Differential; GABA-B Receptor Agonists; | 2015 |
[Aggression and restlessness following baclofen overdose: the narrow line between intoxication and withdrawal symptoms].
Topics: Adult; Aggression; Alcoholism; Baclofen; Delirium; Drug Overdose; GABA-B Receptor Agonists; Humans; | 2016 |
Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Topics: Alcohol Drinking; Alcoholism; Algorithms; Baclofen; Cohort Studies; Drug Monitoring; Follow-Up Studi | 2017 |
Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alcoholism; Bac | 2017 |
Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008-2013.
Topics: Adolescent; Adult; Aged; Alcoholism; Baclofen; Cause of Death; Dose-Response Relationship, Drug; Dru | 2017 |
Comment on: "Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France".
Topics: Adverse Drug Reaction Reporting Systems; Alcoholism; Baclofen; France; Humans; Off-Label Use; Pharma | 2017 |
Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in F
Topics: Adverse Drug Reaction Reporting Systems; Alcoholism; Baclofen; France; Humans; Off-Label Use; Pharma | 2017 |
Baclofen-Related Mania: Lower Threshold for Bipolar Patients?
Topics: Alcoholism; Baclofen; Bipolar Disorder; GABA-A Receptor Agonists; Humans; Male; Middle Aged | 2017 |
Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783--comparison with the effect of the GABAB receptor direct agonist, baclofen.
Topics: Alcoholism; Animals; Baclofen; Behavior, Animal; Central Nervous System Depressants; Cyclopentanes; | 2008 |
Relationship between the hypothalamic-pituitary-thyroid axis and alcohol craving in alcohol-dependent patients: a longitudinal study.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; Female; Humans; Hypothalamo-Hypo | 2008 |
[Alcoholism: history is not finished...].
Topics: Alcoholism; Animals; Baclofen; Disease Models, Animal; Follow-Up Studies; GABA Agonists; Neurokinin- | 2008 |
[Suppression of alcoholism with baclofen: a physician's personal story].
Topics: Alcoholism; Baclofen; GABA Agonists; Humans; Male; Middle Aged; Physician Impairment; Self Care; Sel | 2008 |
Complete suppression of craving in alcohol-dependent individuals: is it possible?
Topics: Alcohol Deterrents; Alcoholism; Baclofen; Behavior, Addictive; Clinical Trials as Topic; Humans | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism | 2009 |
Role of the GABA(B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives.
Topics: Alcoholism; Animals; Baclofen; GABA-B Receptor Agonists; Humans; Receptors, GABA-B; Stress, Psycholo | 2009 |
Behavioral disinhibition with baclofen.
Topics: Aged; Alcoholism; Baclofen; Behavioral Symptoms; GABA-B Receptor Agonists; Humans; Inhibition, Psych | 2010 |
Baclofen-induced morbiliform rashes: a case series.
Topics: Adult; Alcoholism; Baclofen; Exanthema; Female; GABA-B Receptor Agonists; Humans; Male | 2011 |
High-dose baclofen for suppression of alcohol dependence.
Topics: Alcoholism; Baclofen; Female; GABA Agonists; Humans; Male | 2011 |
Baclofen effect related to liver damage.
Topics: Alcoholism; Baclofen; Female; GABA Agonists; Humans; Male | 2011 |
Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy.
Topics: Alcoholism; Baclofen; Controlled Clinical Trials as Topic; Financial Support; GABA-B Receptor Agonis | 2011 |
Baclofen-induced acute hepatitis in alcohol-dependent patient.
Topics: Acute Disease; Alcoholism; Baclofen; Chemical and Drug Induced Liver Injury; Female; GABA-B Receptor | 2011 |
[Baclofen for alcohol addiction].
Topics: Alcoholism; Baclofen; Evidence-Based Medicine; GABA-B Receptor Agonists; Humans; Muscle Relaxants, C | 2011 |
[Baclofen will also have to be compared with approved medications of alcohol dependence].
Topics: Alcoholism; Baclofen; Drug Approval; Humans | 2012 |
[Misuse of alcohol and new drug treatments].
Topics: Alcoholism; Antipsychotic Agents; Aripiprazole; Baclofen; GABA-B Receptor Agonists; Humans; Ondanset | 2011 |
Alcohol-dependence: the current French craze for baclofen.
Topics: Alcoholism; Baclofen; France; GABA Agonists; Humans | 2012 |
High-dose baclofen for treatment-resistant alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Baclofen; Dose-Response Relationship, Drug; Female; GABA-B Rece | 2012 |
Levetiracetam in the treatment of alcohol dependence: toward the end of the story?
Topics: Alcoholism; Anticonvulsants; Baclofen; Double-Blind Method; GABA Agonists; Humans; Levetiracetam; Pi | 2012 |
Baclofen for the treatment of alcohol dependence.
Topics: Alcoholism; Baclofen; Clinical Trials as Topic; GABA-B Receptor Agonists; Humans | 2012 |
Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice.
Topics: Adolescent; Alcohol Drinking; Alcoholism; Analysis of Variance; Animals; Baclofen; Disease Models, A | 2013 |
Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats.
Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Disease Models, Animal; Ethanol; | 2003 |
Rats on the grog: novel pharmacotherapies for alcohol craving.
Topics: Alcoholism; Animals; Baclofen; Beer; Behavior, Addictive; Cannabinoid Receptor Antagonists; Corticot | 2004 |
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord | 2004 |
Tolerance to baclofen's sedative effect in alcohol-addicted patients: no dissipation after a period of abstinence.
Topics: Alcohol Withdrawal Delirium; Alcoholism; Baclofen; Drug Interactions; Drug Tolerance; Ethanol; Human | 2005 |
Naltrexone treatment for alcohol dependency.
Topics: Administration, Oral; Alcoholism; Animals; Baclofen; Ethanol; GABA Agonists; Humans; Naltrexone; Nar | 2005 |
The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats.
Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Conditioning, Operant; Data Inter | 2007 |
Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Behavior, Addictive; GABA Agonists; Humans; Male; Middle Age | 2007 |
GABAergic modulation of binge-like ethanol intake in C57BL/6J mice.
Topics: Alcoholism; Animals; Baclofen; Central Nervous System Depressants; Darkness; Dose-Response Relations | 2007 |
GABAergic medications for treating alcohol dependence.
Topics: Alcoholism; Baclofen; Drug Therapy, Combination; GABA Agonists; gamma-Aminobutyric Acid; Humans; Hyd | 2007 |
Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review.
Topics: Alcoholism; Baclofen; Humans; Retrospective Studies; Substance Withdrawal Syndrome | 2007 |
Growth hormone response to the GABA-B agonist baclofen in 3-week abstinent alcoholics.
Topics: Administration, Oral; Adult; Alcoholism; Baclofen; Case-Control Studies; GABA Agonists; GABA-B Recep | 2007 |
Are the effects of gamma-hydroxybutyrate (GHB) treatment partly physiological in alcohol dependence?
Topics: Alcoholism; Baclofen; GABA Agonists; GABA-B Receptor Agonists; Humans; Sodium Oxybate | 2008 |
Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats.
Topics: Alcoholism; Animals; Baclofen; Behavior, Animal; Choice Behavior; Disease Models, Animal; Ethanol; L | 2008 |
The effects of ethanol, phenobarbital, and baclofen on ethanol withdrawal in the rhesus monkey.
Topics: Alcoholism; Animals; Ataxia; Baclofen; Behavior, Animal; Drug Interactions; Ethanol; Humans; Macaca | 1980 |
Alcoholism abolishes the gamma-aminobutyric acid (GABA)ergic control of GH secretion in humans.
Topics: Adult; Alcoholism; Baclofen; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Human Growth Hormo | 1998 |
Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence.
Topics: Alcohol Drinking; Alcoholism; Animals; Baclofen; Dose-Response Relationship, Drug; Drug Evaluation, | 2000 |
Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.
Topics: Adult; Alcohol Drinking; Alcoholism; Animals; Baclofen; Combined Modality Therapy; Dose-Response Rel | 2000 |
Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics.
Topics: Adult; Alcoholism; Baclofen; Biomarkers; GABA Agents; GABA Agonists; gamma-Aminobutyric Acid; Growth | 2001 |